Biomarkers in cervical cancer screening - PubMed (original) (raw)
Review
Biomarkers in cervical cancer screening
Nicolas Wentzensen et al. Dis Markers. 2007.
Abstract
In industrialized countries, population wide cytological screening programs using the Pap test have led to a substantial reduction of the incidence of cervical cancer. Despite this evident success, screening programs that rely on Pap-stained cytological samples have several limitations. First, a number of equivocal or mildly abnormal test results require costly work up by either repeated retesting or direct colposcopy and biopsy, since a certain percentage of high grade lesions that require immediate treatment hide among these unclear test results. This work up of mildly abnormal or equivocal cytological tests consumes a large amount of the overall costs spent for cervical cancer screening. Improved triage of these samples might substantially reduce the costs. Cervical cancer is induced by persistent infections with oncogenic human papilloma viruses (HPV). While HPV infection is an indispensable factor, it is not sufficient to cause cancer. The majority of acute HPV infections induce low grade precursor lesions that are cleared spontaneously after several months in more than 90% of cases, and less than 10% eventually progress to high grade lesions or invasive cancer. Progression is characterized by the deregulated expression of the viral oncogenes E6 and E7 in infected basal and parabasal cells. Novel biomarkers that allow monitoring these essential molecular events in histological or cytological specimens are likely to improve the detection of lesions that have a high risk of progression in both primary screening and triage settings. In this review, we will discuss potential biomarkers for cervical cancer screening with a focus on the level of clinical evidence that supports their application as novel markers in refined cervical cancer screening programs.
Similar articles
- New markers for cervical dysplasia to visualise the genomic chaos created by aberrant oncogenic papillomavirus infections.
von Knebel Doeberitz M. von Knebel Doeberitz M. Eur J Cancer. 2002 Nov;38(17):2229-42. doi: 10.1016/s0959-8049(02)00462-8. Eur J Cancer. 2002. PMID: 12441259 Review. - [Aspects of molecular pathogenesis of cervical cancer in establishing new tumor markers for early detection and diagnosis].
von Knebel Doeberitz M. von Knebel Doeberitz M. Zentralbl Gynakol. 2001 Apr;123(4):186-91. doi: 10.1055/s-2001-14775. Zentralbl Gynakol. 2001. PMID: 11370525 Review. German. - Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening.
Naucler P, Ryd W, Törnberg S, Strand A, Wadell G, Elfgren K, Rådberg T, Strander B, Forslund O, Hansson BG, Hagmar B, Johansson B, Rylander E, Dillner J. Naucler P, et al. J Natl Cancer Inst. 2009 Jan 21;101(2):88-99. doi: 10.1093/jnci/djn444. Epub 2009 Jan 13. J Natl Cancer Inst. 2009. PMID: 19141778 - Viral and cellular biomarkers in the diagnosis of cervical intraepithelial neoplasia and cancer.
Tornesello ML, Buonaguro L, Giorgi-Rossi P, Buonaguro FM. Tornesello ML, et al. Biomed Res Int. 2013;2013:519619. doi: 10.1155/2013/519619. Epub 2013 Dec 9. Biomed Res Int. 2013. PMID: 24383054 Free PMC article. Review. - Comparison of HPV-based assays with Papanicolaou smears for cervical cancer screening in Morelos State, Mexico.
Salmerón J, Lazcano-Ponce E, Lorincz A, Hernández M, Hernández P, Leyva A, Uribe M, Manzanares H, Antunez A, Carmona E, Ronnett BM, Sherman ME, Bishai D, Ferris D, Flores Y, Yunes E, Shah KV. Salmerón J, et al. Cancer Causes Control. 2003 Aug;14(6):505-12. doi: 10.1023/a:1024806707399. Cancer Causes Control. 2003. PMID: 12948281
Cited by
- Distribution of 14 High-Risk HPV Types and p16/Ki67 Dual-Stain Status in Post-Colposcopy Histology Results: Negative, Low- and High-Grade Cervical Squamous Intraepithelial Lesions.
Mazurec K, Trzeszcz M, Mazurec M, Kobierzycki C, Jach R, Halon A. Mazurec K, et al. Cancers (Basel). 2024 Oct 5;16(19):3401. doi: 10.3390/cancers16193401. Cancers (Basel). 2024. PMID: 39410021 Free PMC article. - Relationship between p16/ki67 immunoscores and PAX1/ZNF582 methylation status in precancerous and cancerous cervical lesions in high-risk HPV-positive women.
Luo H, Lian Y, Tao H, Zhao Y, Wang Z, Zhou J, Zhang Z, Jiang S. Luo H, et al. BMC Cancer. 2024 Sep 20;24(1):1171. doi: 10.1186/s12885-024-12920-4. BMC Cancer. 2024. PMID: 39304838 Free PMC article. - Bridging the gap in cervical cancer screening for underserved communities: MCED and the promise of future technologies.
Alshammari AH, Ishii H, Hirotsu T, Hatakeyama H, Morishita M, di Luccio E. Alshammari AH, et al. Front Oncol. 2024 Jul 29;14:1407008. doi: 10.3389/fonc.2024.1407008. eCollection 2024. Front Oncol. 2024. PMID: 39135996 Free PMC article. Review. - Association between p16/Ki-67 dual stain cytology results prior to and 6 months after LLETZ treatment for CIN and the follow-up regimen three years after treatment: a retrospective cohort study.
Packet B, Goyens J, Weynand B, Poppe W, Dewilde K. Packet B, et al. Arch Gynecol Obstet. 2024 Jul;310(1):493-499. doi: 10.1007/s00404-024-07553-8. Epub 2024 May 28. Arch Gynecol Obstet. 2024. PMID: 38806944 - Molecular triaging options for women testing HPV positive with self-collected samples.
Taghavi K, Zhao F, Downham L, Baena A, Basu P. Taghavi K, et al. Front Oncol. 2023 Sep 22;13:1243888. doi: 10.3389/fonc.2023.1243888. eCollection 2023. Front Oncol. 2023. PMID: 37810963 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials